A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors

I9L-MC-JZCA -

The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
No
Enrollment Goal
60
Trial Dates
Nov 17, 2017 - May 4, 2020
How long will I be in the trial?
Your participation in this trial could last up to 24 months, depending on your cancer type and how you and your tumor respond.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.